Treatment Considerations for ASCVD & LDL-C Management

 

C

ENDO 2022: Targeting PCSK9 for LDL-C Reduction

By Connie Newman
1,812 views
October 5, 2022
1 Comment
Login to view comments. Click here to Login
Treatment Considerations for ASCVD & LDL-C Management
17:04
Canadian Collaborative Research Network

Non-Statin Therapies for Elevated LDL-C: The Role of Inclisiran (and…

Feat. J. Genest
42:26
Scripps Health

Familial Hypercholesterolemia: From Diagnosis to Treatment

Feat. P. Duell
12:20
Seth Martin

HID 2023 Insights: LDL-C - How Low Can We Go Safely?

33:43
Jefferson Health

Update on Lipids: Current Options for Lowering LDL to Reduce CV Risk

Feat. A. Cohen
42:28
Houston Methodist DeBakey Heart and Vascular Center

Treatment of Lipids in 2023: Where Are We Now and Where Are We Going?

Feat. C. Ballantyne
14:50
AHA 2022 Conference Coverage

AHA 2022: Long-Term Efficacy and Safety of Inclisiran in Patients Wi…

Feat. K. Ray
23:35
Connie Newman

ENDO 2022: Targeting PCSK9 for LDL-C Reduction

39:44
The Texas Heart Institute

Lipid Lowering Therapies: Where Did We Start, Where We Are Now and W…

Feat. S. Virani
21:27
Scripps Health

Lipids Update: Current Guidelines for Lipid Management

Feat. S. R. Mehta
30:02
Metabolic Health Summit

Lipid Management & Low Carb Diets

Feat. B. Scher
41:22
Scripps Health

Non-Statin Pharmacotherapies for Risk Reduction

Feat. M. Wilkinson
27:51
Scripps Health

Lipids Update: Overview of Current Guidelines for Lipid Management

Feat. D. Cork